PCR Technologies Market Set to Reach USD 23.67 Billion by 2030

In 2023, the revenue from the PCR technologies market totalled USD 13,709.3 million, with a projected compound annual growth rate (CAGR) of 8.4% through the forecast period. This growth is anticipated to propel the market to reach USD 23,672.5 million by 2030.

This can be credited to the surge in communicable illness and genetic disorder occurrence and the surge in investments to advance diagnostic techs. Furthermore, the growing awareness of initial disease analysis and novelties in products is projected to boost the development of this industry.

In 2023, Reagents and consumables had the largest share, of more than 70%, and this category is projected to lead the product segment throughout the projection period. This is mainly because of the regular use of consumables and reagents for PCR testing. Basically, the growing occurrence of communicable diseases, particularly COVID-19, propels the industry in this category.

In 2023, real-time polymerase chain reaction held the largest share, and this category is projected to have a substantial CAGR, of 8%, during the projection period. This is mainly because it is one of the most extensively utilized methods throughout the globe in an extensive variety of applications, like species abundance quantification, cancer phenotyping, diagnostic test development, and gene expression analysis.

In 2023, the North American region accounted for the largest share, of 40%, and the region is projected to remain dominant in the future as well. This can be credited to the surge in the occurrence of communicable illness, improvement in the healthcare infrastructure, and the launch of advanced PCR instruments and consumables by key companies.

Read More

Isothermal Nucleic Acid Amplification Technology Market is Led by Hospitals

The isothermal nucleic acid amplification technology market was sized at USD 4,425.5 million in 2023, which will power at a rate of 9.4% by the end of this decade, to touch USD 8,159.4 million by 2030. This has a lot to do with the considerable rise in its use as a molecular testing method as a result of the increasing occurrence of communicable diseases.

TB, influenza, and hepatitis are amongst the main causes of death traceable to communicable ailments, particularly in developing nations.

Infectious diseases are a key reason for mortality and morbidity at a global level. This is why the snowballing incidence of communicable diseases is a key factor for the industry growth.

North America isothermal nucleic acid amplification technology market was the leader of the pack with around 45%, in 2023, and there will be a considerable growth in the years to come as well. This will be because of the recognized research infra and surge in the requirement for nucleic-acid-amplification-based diagnostics to for averting pandemics in the region.

The German market has a considerable share in Europe because of the rising elderly populace and considerable emphasis on the healthcare infra. As per the World Bank, the nation’s population, which was more than 65 years was around 19 million in 2021. These large elderly population will bring about a high prevalence of age-related ailments and communicable diseases. which would reinforce the market prospects for effective INAAT devices and reagents.

It is because of the changing lifestyles in developing countries of the world, the demand for isothermal nucleic acid amplification technology is on the rise. This trend will continue in the years to come as well.

Read More

Influenza Diagnostics Market is Driven by the Expansion of Government Screening Programs

The influenza diagnostics market was valued at USD 946.9 million in 2023, which will rise to a total value of USD 1,603.1 million by 2030, powering at a compound annual growth rate of 7.9% by the end of this decade.

The necessity for influenza diagnosis solutions will rise because of the snowballing occurrence of chronic illnesses, numerous of which are deteriorated by the flu; rising elderly populace, and growing government actions to monitor the disease spread. The growth of tech sophisticated diagnostic tools for the infection is an additional key driver of the industry.

The growing occurrence of influenza at the global level has encouraged the launch of research and development initiatives to advance the detection and treatment. Most of the research is directed at making quicker and more-accurate diagnostic tools for flu viruses.

The test kits and reagents category was the leader of the pack with a share of 60% in 2023. This has a lot to do with the substantial incidence of communicable diseases and rising consciousness with regards to their early diagnosis.

The compensations of test kits, such as their easy convenience at retail stores, pharmacies, and online distribution channels without the requirement for a prescription, ease of use, fast results, and affordability, will drive the growth of the category.

With the usage of over-the-counter test kits, anxieties about spreading the flu are eliminated, as they allow one to get tested in separation, without coming near other individuals, who may be carriers. Moreover, POC testing also removes the necessity for healthcare professionals, reducing expenses because of their user-friendliness.

Also, the instruments category will grow the fastest at a rate of 8.3% in the influenza diagnostics market, by the end of this decade. This is credited to the increasing healthcare spending globally, resulting in a surge in the count of hospitals and diagnostic centers, therefore powering the requirement for the instruments used for detecting the existence of the pathogen.

Moreover, the continuing research studies and developing technologies are the main contributors. Furthermore, as a result of their sensitivity and specificity, they offer higher reliability than test kits, fueling their use quickly.

It is because of the significant increase in the number of government screening programs all over the world, the demand for influenza diagnostics solutions will be on the rise. This will be trending in the near future as well.

Read More

North America was the Leader of the Multiplex Assays Market

The multiplex assays market produced USD 3,918 million revenue in 2023, and it will power at a rate of 9% by the end of this decade, touching USD 7,103.5 million by 2030.

To learn more about this report: https://bit.ly/4aNVHAn

The main factor powering the industry is the growing incidence of chronic ailments and infectious diseases. Also, the growing requirement for effective analytical platforms in research and medical diagnostics, to decrease the costs for researchers, healthcare providers, and patients, is a robust contributor.

On the basis of product, the consumables category led the industry with a share, of 45%, in 2023. It was because of the increase in the count of diagnostic tests and surge in research actions by life sciences companies.

For example, in January 2023, Novo Nordisk, a pharma company, publicized a USD 6-million grant for Durham Technical Community College, for supporting the later’s life sciences program and set up a novel training center with area of 35,000 square feet.

The protein-based category led the multiplex assays market, with a 50%, share in 2023, due to the growing applications of these kinds of products in proteomics studies. Furthermore, protein-based assays are extensively used in research to recognize the protein concentration, electrophoresis, cell biology and other analytes.

The flow cytometry category led the industry in 2023, because of the numerous applications of this tech in the discovery and measurement of proteins and RNA and in the assessment of cell health.

For instance, Life Sciences Core Facilities, the Flow Cytometry Unit, Weizmann Institute of Science’s is making the use of imaging flow analyzers that combine the high-amount quantification of flow cytometry with microscopy and aid in the study of post-translational alterations and protein, protein interactions in different contexts.

North America led the industry with a share of 55%, in 2023, and it will power at a considerable rate, as a result of the increase in the research and development activities by biotech and pharma companies for the expansion of new drugs and diagnostic solutions. 

For example, in Jan 2023, PharmaEssentia Corporation publicized plans for a new PIRC in Greater Boston, Massachusetts. Likewise, in October 2022, Lineage Cell Therapeutics Inc. publicized the opening of a novel research and development facility in California and the development of its GMP-compliant capability in Israel. Lineage’s novel facility in California will extend its R&D competences in the U.S. and support the expansion of present and future allogeneic cell transplant programs.

It is because of the growing prevalence of chronic and infectious diseases all over the world, the demand for multiplex assays is on the rise. This trend will also continue in the years to come as well.

Read More

North America Is Dominating Pyrogen Test Market

Revenue of USD 1,406.4 million was generated in the global pyrogen test market for 2023, which is expected to grow at a compound annual growth rate of 7.3% over the period from 2024 to 2030 and reach USD 2,284.2 million. This growth of the market can be credited to the increasing acceptance of pyrogen testing within the biopharmaceutical sector.

To learn more about this report: https://bit.ly/3viQeS0

Furthermore, the rising development in the biotechnology and pharmaceutical industries along with the increasing count of new biologics research and introductions is projected to fuel the demand for these testing for making safe and better drugs.

Pyrogen testing is a vital step for each medication and therapeutics to make it safer and more effective. Surge in the count of cancer cases and hereditary illnesses, modified treatments attained benefits in the treatment of these diseases.

Tailored medicine has the benefit that it uses people’s hereditary profiles to aid in decision-making for the prevention, diagnosis, and treatment of illnesses. Therefore, patients and businesses are quickly accepting modified drugs. Furthermore, modified treatment-based methods to clinical and genomic features are becoming more popular among patients with cancer and immunologic sicknesses. Hence, the increasing need for modified drugs is one of the key reasons propelling the demand for pyrogen testing solutions.

In the North American region, the U.S. dominates the industry. This is mainly because of the existence of advanced healthcare infrastructure, augmented concentration on new drug growth, and the presence of key biotechnology and biopharmaceutical companies, like Pfizer Inc. and F. Hoffmann-La Roche AG, in the country.

Furthermore, Canada is also generating substantial revenue for the North American industry. This can be credited to the rising pharmaceutical and biotechnology sector, the rising awareness regarding the safety of medications, and the growing R&D activities in the country.

Read More

Transplant Diagnostics Market was Led by the Molecular Assays Category

The transplant diagnostics market was valued at USD 4,686.7 million in 2023, and it will grow at a rate of 7.5% by the end of this decade, to touch USD 7,713.5 million by 2030.

To learn more about this report: https://bit.ly/3vek5es

This is attributable to the growing requirement for organ replacement procedures, the growing requirement for diagnostic procedures before organ replacement, and the powering occurrence of communicable diseases. 

Also, the number of people with final-stage organ failure is on the rise, and because of the development in organ transplantation procedures, a high number of patients can now access these surgeries.

On the basis of technology, molecular assay led the industry with a share, of 65%, in 2023, and it will continue to dominate in the future as well.

The diagnostics category dominated the transplant diagnostics market, with a share of 70%, in 2023, and it will continue like this in the future. This is credited to the increasing occurrence of ailments.

Furthermore, the diagnostic category is divided into pre-transplantation and post-transplantation diagnostic. Additionally, for transplant processes, all relative diagnostic tests will be done prior to the transplant to see the compatibility of the transplant for example blood profiling, histocompatibility testing, and communicable disease testing.

North America had the largest share, of 50%, in 2023, and it will continue like this in the future. This has a lot to do with the high acceptance rate of cutting-edge techniques and analytic tools, high healthcare spending, the obtainability of skilled experts, and the extensive use of soft tissue transplants, stem cell therapies, and tailored medications.

Furthermore, the growing count of organ replacements, the increasing consciousness of transplantation, the growing incidence of communicable ailments, and the rising elderly populace susceptible to chronic ailments are powering the industry.

There is an increasing number of organ transplants happening around the world, and this will power the demand for transplant diagnostic solutions. The trend will continue in the years to come as well.

Read More

Fill-Finish Manufacturing Market is Led by the Asia-Pacific Region

The fill-finish manufacturing market made a revenue of USD 10.1 billion in 2023, and it will touch a value of USD 20.7 billion by 2030, powering at a rate of 10.9% by the end of this decade, powered by the increasing requirement for injectables, as well as biologics and modified medicines.

This procedure plays a significant role in the pharma and biotech sectors by being the last stage in the production process, wherein biologic and synthetic drugs are dispensed into their containers and packed for distribution.

On the basis of the product, consumables led the industry with a share of 65%, in 2023, and it will be like this in the future as well. Consumables put to use in in the fill−finish procedure comprise vials, cartridges, syringes, caps, seals, stoppers, and filters.

APAC was the leader of the pack, with a share of about 45%, in 2023, and this trend will continue in the years to come as well. The main region for this is that the region has a strong presence of pharma and biotech companies.

China, Japan, India, and South Korea are the hubs for pharma production and R&D activities. These have well-established pharma infra, a large and skilled workforce, and advantageous guidelines of the government supporting the development of related businesses. 

Furthermore, more than a few biotech and pharma companies from Europe and North-America outsource their final-stage production process to firms based in the region on contract.

It is because of the growing demand for injectables and continuous advancements in technology all over the world, the demand for fill-finish manufacturing is on the rise, This trend will continue in the years to come as well.

Read More

Allergy Diagnostics Market is Led by North America

The allergy diagnostics market is estimated to reach USD 6,103.3 million in 2023, which will touch USD 12,814.2 million, with an 11.2% compound annual growth rate, by 2030.

The growth of this industry is because of the rising levels of environmental pollution, increasing investment to enhance allergy diagnostics by private & public administrations, and the occurrence of allergic disorders.

Furthermore, the inactive lifestyles, characterized by smoking, consumption of alcohol, and poor food habits; coupled with the high demand for in-vitro blood testing will further boost the industry expansion.

The consumables category, based on offering, is leading the industry in 2023, with a 45% share. This can be because consumables are an important component in detecting allergies.

North America is leading the industry in 2023, with a 55% share. This can be because of the strong healthcare system, swift technological developments in the medical sector, and advantageous reimbursement rules.

Additionally, the surging occurrence of allergies, coupled with the presence of inspiring procedures by associations to increase consciousness and make treatment and diagnosis available are also major contributors.

APAC will progress at the highest rate, of 11.5%, in the years to come. This can be primarily attributed to the requirement for less-invasive diagnostic technologies, speedily growing medical infrastructure, surging medical tourism activities, and unfulfilled clinical requirements.

With the rising levels of environmental pollution, the allergy diagnostics industry will continue to progress in the years to come.

Read More

North America Is Dominating In-Situ Hybridization Industry

In 2023, the in-situ hybridization market amounted to USD 1,742.3 million and is set to grow at a compound annual growth rate of 12.8% between 2024 and 2030 reaching an estimated amount of USD 4,017.3 million by 2030.

This development of the market can be credited to the increasing acceptance of the in-situ hybridization (ISH) process for identifying numerous genetic illnesses and cancer, the rising pace of improvements in this method, and growing private and public funding for the research and development sector. Moreover, the rising demand for modified medicines is projected to fuel the industry growth.

There has been a distressing surge in cases of cancer worldwide in the past few years. This has caused a surge in the number of examined studies connected with this illness and those revolving around certain genomic irregularities, which are likely risk factors for numerous types of carcinomas.

In 2023, the FISH technology had a significant share, credited to the extensive variety of applications of this tech in diagnostics, like characterization with the aid of marker chromosomes, finding of numerical and structural chromosome flaws, finding of unusual and hereditary conditions, and drug abuse tracking.

In 2023, the North American region, generated the largest revenue share, of 55%, in the worldwide industry for in-situ hybridization solutions. The North American industry is projected to continue to uphold its dominating position during the projection period, mainly credited to the increasing count of autosomal diseases, cancer cases, genetic disorders, and also communicable conditions in the continent.

The U.S. is the key revenue generator in North America, mainly because of the strong government and private backing for the growth of new companion diagnostics methods.

Read More

Pharmaceutical Sterility Testing Industry IS Dominated by North America

The pharmaceutical sterility testing market will reach USD 2,953.9 million by 2030, growing at a rate of 11.2% during 2023–2030. This is because of the development of biotech and pharma firms, an increase in their R&D activities, an increase in the incidence of diseases, and substantial government spending on the healthcare industry.

To learn more about this report: https://bit.ly/3KQmVer

The increasing occurrence of diseases in the pest has brought about an increase in R&D activities for the manufacturing of effective and safe therapeutics. Regarding this, the continuing studies on the preventing severe viral infections, such as the novel coronavirus, and those centered on the expansion of effective and safe vaccines have a positive impact on the industry.

The occurrence of hematological malignancies is increasing. As per the Leukemia & Lymphoma Society, every 3 minutes, a person is identified with leukemia, myeloma, or lymphoma in the U.S. Biopharma, for example gene, and immune cell therapies are quickly being accepted as a substitute treatment for hematological cancers. This is due to the fact that such therapeutics have high effectiveness and efficacy against these kinds of diseases.

North America pharmaceutical sterility testing market had a major share of 40%, in 2022. This is credited to the presence of leading pharma and biopharma players, increasing R&D activities in the biotech and pharma industry, increasing number of product introductions, high occurrence of chronic ailments, and supportive policies of the government for the setup of R&D facilities. 

Furthermore, Europe follows North America in terms of revenue share. This is attributable to the formation of universal public healthcare systems in numerous nations in the region, which has considerably increased the requirement for healthcare products. The employment of stringent regulatory policies with regards to the safety of drugs is another key factor contributing to the growth of the industry.

The increasing acceptance of digital platforms has a positive impact on the demand for pharmaceutical sterility testing, and this will be the trend in the years to come as well.

Read More